论文部分内容阅读
[目的]评价莫西沙星序安全性。[方法]80例下呼吸道感染者随机分为莫西沙星治疗组和左氧氟沙星对照组进行治疗,评估其不良反应,包括消化道症状(口干、恶心、呕吐、腹部不适等)、头晕、头痛,光敏﹑嗜睡等。[结果]莫西沙星组和左氧氟沙星对照组治疗下呼吸道感染总不良反应分别为7.31%(3/41)和12.82%(5/39)。统计学分析两组间差异均有统计学意义(P﹤0.05)。[结论]莫西沙星序贯疗法400mg是一安全的治疗方法。
[Objective] To evaluate the safety of moxifloxacin. [Methods] Eighty patients with lower respiratory tract infection were randomly divided into the moxifloxacin group and the levofloxacin control group. The adverse reactions were evaluated including gastrointestinal symptoms (dry mouth, nausea, vomiting, abdominal discomfort, etc.), dizziness, headache, Photosensitive ﹑ sleepiness and so on. [Results] The total adverse reactions of lower respiratory tract infection in the moxifloxacin group and the levofloxacin control group were 7.31% (3/41) and 12.82% (5/39), respectively. Statistical analysis of the differences between the two groups were statistically significant (P <0.05). [Conclusion] The sequential treatment of moxifloxacin 400mg is a safe treatment.